Eleni Stamellou

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Different design of enzyme-triggered CO-releasing molecules (ET-CORMs) reveals quantitative differences in biological activities in terms of toxicity and inflammation

Eleni Stamellou, D. Storz, Svetlana Botov et al. · Redox Biology · 2014 · 83 citations · Full text

Enzyme-triggered CO-releasing molecules (ET-CORMs): Evaluation of biological activity in relation to their structure

Steffen Romanski, Eleni Stamellou, J.T. Jaraba et al. · Free Radical Biology and Medicine · 2013 · 64 citations

Biological Activity, Protein Chemistry, Biochemistry +8